Table 2.
Treatment-emergent adverse events
| Adverse events | Adalimumab 80 mg EOW (n = 28) |
|---|---|
| All adverse events | 24 (85.7) |
| Serious adverse events | 8 (28.6) |
| Adverse events leading to discontinuation of therapy | 4 (14.3) |
| Any infection | 19 (67.9) |
| Serious infection | 2 (7.1) |
| Malignant adverse event | 0 |
| Injection site reaction | 1 (3.6) |
| Opportunistic infections (excluding tuberculosis) | 0 |
| Demyelinating disease | 0 |
| Tuberculosis | 0 |
| Allergic reactions including angioedema/anaphylaxis | 2 (7.1) |
| Lupus-like syndrome | 0 |
Values are n (%). EOW, every other week.